A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects

Completed · Phase 1

Conditions studied: Morbid Obesity

In brief

This study will determine how morbid obesity affects the distribution and metabolism of the drug propofol. The investigators hypothesize that propofol will be distributed and metabolized differently in morbidly obese subjects as compared to normal weight subjects.

Key facts

Study ID

NCT01591148

Run by

Stanford University

People needed

30

Starts

2011-01-01

Expected to finish

2017-07-01

Last updated by the study team

2017-12-29

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adult age (ages 18-70)
• body mass index greater than 40 or between 20-25
• American Society of Anesthesiologists Class I, II, or III
• undergoing elective surgical procedure requiring general anesthesia

You may not qualify if…

• evidence of cardiovascular or pulmonary disease
• kidney or liver dysfunction
• drug allergy to propofol
• history of difficult airway
• on prescribed or over the counter anxiolytics, antipsychotics, or sleeping aids
• unable to speak or understand English

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.